search
Back to results

Hyperapo B and Coronary Heart Disease

Primary Purpose

Cardiovascular Diseases, Coronary Disease, Heart Diseases

Status
Completed
Phase
Locations
Study Type
Observational
Intervention
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Cardiovascular Diseases

Eligibility Criteria

undefined - 100 Years (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

No eligibility criteria

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    May 25, 2000
    Last Updated
    February 17, 2016
    Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00005168
    Brief Title
    Hyperapo B and Coronary Heart Disease
    Study Type
    Observational

    2. Study Status

    Record Verification Date
    May 2000
    Overall Recruitment Status
    Completed
    Study Start Date
    August 1984 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    December 1991 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    5. Study Description

    Brief Summary
    To determine the role of apolipoprotein B and apolipoprotein A1 in the etiology of coronary artery disease.
    Detailed Description
    BACKGROUND: Hyperapo B is a phenotype defined as elevated plasma level of the major apoprotein B of low density lipoproteins in the presence of a normal plasma level of low density lipoprotein cholesterol. It has been demonstrated that hyperapo B is strongly associated with coronary artery disease. In 1984 when the study began, the independence of this association with other risk factors for coronary artery disease such as cigarette smoking, hypertension, and low plasma levels of high density lipoproteins was not known. The study improved knowledge of the pathophysiology of coronary artery disease and of the genetic and biochemical defects of hyperapo B and hypoalphalipoproteinemia. DESIGN NARRATIVE: Interviews were conducted and clinical data collected on each index case and spouse, as well as on first degree relatives. Risk factor data included blood pressure, blood lipid levels, obesity, cigarette smoking, fasting blood sugar and diabetes, hormone use and menopause for women, physical activity, personality scores, and family history. Clinical data included the indications for coronary arteriography, history of use of lipid-lowering agents and insulin, presence of corneal arcus, xanthomata, and xanthelasma, and the electrocardiogram. To determine if the apolipoprotein B gene and the apolipoprotein A1-C3-A4 gene cluster were independent predictors of premature coronary disease, the relation between DNA polymeric sites within the two genes and coronary disease were investigated using cloned DNA fragments as molecular probes. To determine if apolipoprotein B and apolipoprotein A levels aggregated in families and to determine if hyperapo B and hypoalphalipoproteinemia segregated as Mendelian traits, genetic analysis was conducted in the 200 index cases and the 900 first degree relatives. Studies were also conducted on the linkages between hyperapo B and haplotypes of the apolipoprotein B gene, on hyperapo B and the Ag polymorphisms, and on hyperalphalipoproteinemia and haplotypes of the apolipoprotein A1-C3-A4 gene cluster. The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cardiovascular Diseases, Coronary Disease, Heart Diseases, Diabetes Mellitus, Obesity, Hypercholesterolemia, Familial

    7. Study Design

    10. Eligibility

    Sex
    Male
    Maximum Age & Unit of Time
    100 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    No eligibility criteria

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    6422918
    Citation
    Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis. 1984 Mar-Apr;4(2):79-83. doi: 10.1161/01.atv.4.2.79. No abstract available.
    Results Reference
    background
    PubMed Identifier
    3969864
    Citation
    Sniderman A, Teng B, Genest J, Cianflone K, Wacholder S, Kwiterovich P Jr. Familial aggregation and early expression of hyperapobetalipoproteinemia. Am J Cardiol. 1985 Feb 1;55(4):291-5. doi: 10.1016/0002-9149(85)90363-7.
    Results Reference
    background
    PubMed Identifier
    2580831
    Citation
    Teng B, Sniderman A, Krauss RM, Kwiterovich PO Jr, Milne RW, Marcel YL. Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses. J Biol Chem. 1985 Apr 25;260(8):5067-72.
    Results Reference
    background
    PubMed Identifier
    4059254
    Citation
    Kwiterovich PO Jr, Bachorik PS, Franklin FA Jr, Margolis S, Georgopoulos L, Teng B, Sniderman AD. Effect of dietary treatment on the plasma levels of lipids, lipoprotein cholesterol and LDL B protein in children with type II hyperlipoproteinemia. Prog Clin Biol Res. 1985;188:123-37.
    Results Reference
    background
    PubMed Identifier
    3706300
    Citation
    Beaty TH, Kwiterovich PO Jr, Khoury MJ, White S, Bachorik PS, Smith HH, Teng B, Sniderman A. Genetic analysis of plasma sitosterol, apoprotein B, and lipoproteins in a large Amish pedigree with sitosterolemia. Am J Hum Genet. 1986 Apr;38(4):492-504.
    Results Reference
    background
    PubMed Identifier
    3707428
    Citation
    Genest J, Sniderman A, Cianflone K, Teng B, Wacholder S, Marcel Y, Kwiterovich P Jr. Hyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load. Arteriosclerosis. 1986 May-Jun;6(3):297-304. doi: 10.1161/01.atv.6.3.297.
    Results Reference
    background
    PubMed Identifier
    3340649
    Citation
    Kwiterovich P, Beaty T, Bachorik P, Chen J, Franklin F, Georgopoulos L, Sniderman A. Pediatric hyperlipoproteinemia: the phenotypic expression of hyperapobetalipoproteinemia in young probands and their parents. Prog Clin Biol Res. 1988;255:89-105.
    Results Reference
    background
    PubMed Identifier
    3593067
    Citation
    Kwiterovich PO Jr, White S, Forte T, Bachorik PS, Smith H, Sniderman A. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. Arteriosclerosis. 1987 May-Jun;7(3):211-25. doi: 10.1161/01.atv.7.3.211.
    Results Reference
    background
    Citation
    Sniderman A, Kwiterovich PO Jr: Hyperapobetalipoproteinemia and LDL and HDL2 Heterogenity. Proceedings of the Workshop on Lipoprotein Heterogeneity, U.S. Department of Health and Human Services, NIH Publication No. 87-2646, pp 293-304, 1987
    Results Reference
    background
    PubMed Identifier
    2723545
    Citation
    Beaty TH, Kwiterovich PO, Laville A, Lewis B. Genetic analysis of total cholesterol and triglycerides in a pedigree of St. Thomas rabbits. J Lipid Res. 1989 Mar;30(3):387-94.
    Results Reference
    background
    PubMed Identifier
    2461193
    Citation
    Ma YH, Ladias JA, Butler R, Schumaker VN, Antonarakis SE, Lusis AJ, Heinzman C, Kwiterovich PO. Apolipoprotein B gene haplotypes. Association between Ag and DNA polymorphisms. Arteriosclerosis. 1988 Sep-Oct;8(5):521-4. doi: 10.1161/01.atv.8.5.521.
    Results Reference
    background
    PubMed Identifier
    3141687
    Citation
    Kwiterovich PO Jr. Biochemical, clinical, genetic and metabolic studies of hyperapo-beta-lipoproteinaemia. J Inherit Metab Dis. 1988;11 Suppl 1:57-73. doi: 10.1007/BF01800571.
    Results Reference
    background
    PubMed Identifier
    3042202
    Citation
    Kwiterovich PO Jr. HyperapoB: a pleiotropic phenotype characterized by dense low-density lipoproteins and associated with coronary artery disease. Clin Chem. 1988;34(8B):B71-7.
    Results Reference
    background
    PubMed Identifier
    3067911
    Citation
    Bachorik PS, Kwiterovich PO Jr. Apolipoprotein measurements in clinical biochemistry and their utility vis-a-vis conventional assays. Clin Chim Acta. 1988 Nov;178(1):1-34. doi: 10.1016/0009-8981(88)90265-3.
    Results Reference
    background
    PubMed Identifier
    2778934
    Citation
    Ladias JA, Kwiterovich PO Jr, Smith HH, Miller M, Bachorik PS, Forte T, Lusis AJ, Antonarakis SE. Apolipoprotein B-100 Hopkins (arginine4019----tryptophan). A new apolipoprotein B-100 variant in a family with premature atherosclerosis and hyperapobetalipoproteinemia. JAMA. 1989 Oct 13;262(14):1980-8. doi: 10.1001/jama.262.14.1980.
    Results Reference
    background
    PubMed Identifier
    2698247
    Citation
    Kwiterovich PO. Genetic influences on susceptibility to atherosclerosis in the young. Bull N Y Acad Med. 1989 Dec;65(10):1092-108; discussion 1154-60. No abstract available.
    Results Reference
    background
    PubMed Identifier
    2146310
    Citation
    Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol. 1990 Nov;16(6):862-70. doi: 10.1016/s0735-1097(10)80334-1.
    Results Reference
    background
    PubMed Identifier
    2108924
    Citation
    Ladias JA, Kwiterovich PO Jr, Smith HH, Karathanasis SK, Antonarakis SE. Apolipoprotein A1 Baltimore (Arg10----Leu), a new ApoA1 variant. Hum Genet. 1990 Apr;84(5):439-45. doi: 10.1007/BF00195816.
    Results Reference
    background
    PubMed Identifier
    1459430
    Citation
    Beaty TH, Prenger VL, Virgil DG, Lewis B, Kwiterovich PO, Bachorik PS. A genetic model for control of hypertriglyceridemia and apolipoprotein B levels in the Johns Hopkins colony of St. Thomas Hospital rabbits. Genetics. 1992 Dec;132(4):1095-104. doi: 10.1093/genetics/132.4.1095.
    Results Reference
    background
    PubMed Identifier
    1415250
    Citation
    Prenger VL, Beaty TH, Kwiterovich PO. Genetic determination of high-density lipoprotein-cholesterol and apolipoprotein A-1 plasma levels in a family study of cardiac catheterization patients. Am J Hum Genet. 1992 Nov;51(5):1047-57.
    Results Reference
    background
    PubMed Identifier
    1570833
    Citation
    Coresh J, Beaty TH, Kwiterovich PO Jr, Antonarakis SE. Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels. Am J Hum Genet. 1992 May;50(5):1038-45.
    Results Reference
    background
    PubMed Identifier
    1561971
    Citation
    Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 1992 Apr 15;69(12):1015-21. doi: 10.1016/0002-9149(92)90856-t.
    Results Reference
    background
    PubMed Identifier
    1673959
    Citation
    Heizmann C, Kirchgessner T, Kwiterovich PO, Ladias JA, Derby C, Antonarakis SE, Lusis AJ. DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels. Hum Genet. 1991 Apr;86(6):578-84. doi: 10.1007/BF00201544.
    Results Reference
    background
    PubMed Identifier
    1858776
    Citation
    Miller M, Bell W, Plano S, Connors J, Kennedy S, Kwiterovich P. Platelet aggregation in hyperapobetalipoproteinemia. Am J Hematol. 1991 Jul;37(3):209-11. doi: 10.1002/ajh.2830370317.
    Results Reference
    background
    PubMed Identifier
    2004437
    Citation
    Kwiterovich PO Jr, Motevalli M, Miller M, Bachorik PS, Kafonek SD, Chatterjee S, Beaty T, Virgil D. Further insights into the pathophysiology of hyperapobetalipoproteinemia: role of basic proteins I, II, III. Clin Chem. 1991 Mar;37(3):317-26.
    Results Reference
    background
    PubMed Identifier
    2247473
    Citation
    Kwiterovich P Jr, Motevalli M, Miller M. Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP II. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8980-4. doi: 10.1073/pnas.87.22.8980.
    Results Reference
    background
    PubMed Identifier
    2073916
    Citation
    Miller M, Kwiterovich PO Jr. Isolated low HDL-cholesterol as an important risk factor for coronary heart disease. Eur Heart J. 1990 Dec;11 Suppl H:9-14. doi: 10.1093/eurheartj/11.suppl_h.9.
    Results Reference
    background

    Learn more about this trial

    Hyperapo B and Coronary Heart Disease

    We'll reach out to this number within 24 hrs